DexCom Inc. (DXCM) recently announced the launch of a proprietary Generative AI (GenAI) platform, making Dexcom the first Continuous Glucose Monitoring (CGM) manufacturer to integrate GenAI into glucose biosensing technology.In addition to offering practical insights to support the improvement of metabolic health, the new Dexcom GenAI platform is likely to examine trends in individual health data to uncover a clear correlation between lifestyle decisions and blood glucose levels. Dexcom leveraged Google Clo ...